
Protein Alternatives
A biotechnological company focused on the development and commercialization of biomarker-based assays for cancer diagnosis and therapeutic antibodies for treatment of metastatic tumors.
Date | Investors | Amount | Round |
---|---|---|---|
investor | €0.0 | round | |
investor | €0.0 | round | |
N/A | €0.0 | round | |
* | €1.2m | Grant | |
Total Funding | 000k |
EUR | 2018 | 2019 | 2020 | 2021 |
---|---|---|---|---|
Revenues | 0000 | 0000 | 0000 | 0000 |
% growth | - | (38 %) | 2 % | 363 % |
EBITDA | 0000 | 0000 | 0000 | 0000 |
% EBITDA margin | 429 % | 384 % | 229 % | 98 % |
Profit | 0000 | 0000 | 0000 | 0000 |
% profit margin | 34 % | (90 %) | (167 %) | (14 %) |
EV | 0000 | 0000 | 0000 | 0000 |
EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x |
EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x |
R&D budget | 0000 | 0000 | 0000 | 0000 |
Source: Company filings or news article
Related Content
Protein Alternatives (PROALT) is a biotechnology company focused on advancing cancer diagnostics and therapeutics. The company specializes in developing innovative diagnostic assays for the early detection of cancer and creating unique therapeutic antibodies aimed at novel targets for the effective treatment of metastatic cancers.
PROALT serves a diverse range of clients, including medical institutions, research organizations, and pharmaceutical companies. The company operates in the biotechnology and healthcare market, which is characterized by rapid innovation and a high demand for effective cancer treatments and diagnostic tools.
The business model of PROALT revolves around three main areas: therapeutic antibodies, diagnostic assays, and custom-tailored services. In the therapeutic antibodies segment, PROALT develops antibodies that target specific proteins involved in cancer progression, offering new treatment options for patients with metastatic cancers. In the diagnostic assays segment, the company creates tests that enable the early detection of cancer, which is crucial for improving patient outcomes. Additionally, PROALT provides custom-tailored services and research-use products, catering to the specific needs of its clients in the research and medical fields.
PROALT generates revenue through the sale of its diagnostic assays, therapeutic antibodies, and custom services. The company also collaborates with research institutions and pharmaceutical companies, which can lead to additional funding and partnership opportunities.
In summary, Protein Alternatives is a forward-thinking biotechnology company dedicated to improving cancer diagnostics and treatments. By focusing on innovative solutions and addressing unmet medical needs, PROALT is well-positioned to make a significant impact in the healthcare industry.
Keywords: biotechnology, cancer diagnostics, therapeutic antibodies, metastatic cancer, early detection, medical institutions, research organizations, pharmaceutical companies, custom services, healthcare innovation.